碩世生物(688399.SH)近期股價漲幅較大提示風險 新型冠狀病毒檢測產品已發貨60餘萬人份
格隆匯2月3日丨碩世生物(688399.SH)公佈,公司股票交易連續2個交易日內(2020年1月23日、2020年2月3日)收盤價格漲幅偏離值累計達到30%,根據《上海證券交易所交易規則》《上海證券交易所科創板股票交易特別規定》《上海證券交易所科創板股票異常交易實時監控細則(試行)》的有關規定,屬於股票交易異常波動。
經公司自查,併發函問詢控股股東及實際控制人,截至2020年2月3日,無應披露而未披露的重大信息。
截止公告披露日,公司新型冠狀病毒檢測產品已發貨60餘萬人份,將對公司一季度的收入構成正面影響,但尚不能確定對一季度利潤影響程度,從目前情況看,對2020年全年經營成果不會產生重大影響。公司特別提醒廣大投資者,注意投資風險。
截至2020年2月3日,公司收盤價為117.48元/股,對應公司2018年扣除非經常性損益前後孰低的攤薄後市盈率為123.57倍。截止2020年2月3日,根據中證指數有限公司發佈的公司最新滾動市盈率為112.8倍,公司所處的醫藥製造業最近一個月平均滾動市盈率為35.17倍,顯著高於行業市盈率水平。公司特別提醒廣大投資者,注意投資風險,理性決策,審慎投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.